Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. (JAGX) filed an S-3 shelf registration describing recent financings, intellectual property and product updates tied to its crofelemer franchise and related assets. The filing references a New Private Placement dated September 28, 2025 that issued New PIPE Shares and a Pre-Funded Warrant, and notes a concurrent private placement that closed on May 22, 2025 which included unregistered warrants to purchase 492,612 shares at an exercise price of $5.84 per share.
Clinical and commercial developments disclosed include ongoing investigator-initiated trials (IITs) and placebo-controlled studies of crofelemer for rare GI conditions, with initial Abu Dhabi IIT results showing reductions in total parenteral nutrition by up to 27% in an MVID patient and up to 12.5% in an SBS-IF patient. An abstract was accepted for presentation at NASPGHAN on November 5-8, 2025. The filing also notes that Canalevia-CA1 (crofelemer delayed-release tablets) is conditionally approved for chemotherapy-induced diarrhea in dogs and is commercially available through multiple US veterinary distributors. The document lists numerous certificates of designation for preferred stock series and describes exchange limits and beneficial ownership caps (commonly 19.99% limits) tied to Series N Preferred Stock and certain pre-funded warrants.
Jaguar Health, Inc. entered into a private placement with Brown Stone Capital Limited to issue securities on September 28, 2025. The company agreed to sell 161,583 shares of voting common stock and 479,442 pre-funded warrants exercisable for common stock. The Securities were offered under Rule 506 of Regulation D to an accredited investor. The filing includes a Securities Purchase Agreement and a Pre-Funded Warrant dated September 28, 2025, and is signed by CEO Lisa A. Conte on behalf of Jaguar Health.
Jaguar Health, Inc. (JAGX) filed a Form D Notice reporting a completed private equity offering under Rule 506(b) that raised $2,377,000. The filing identifies the issuer as a Delaware corporation with its principal place of business in San Francisco, CA. The offering sold all securities (Total Amount Sold: $2,377,000; Total Remaining to be Sold: $0) to a total of 15 investors. The minimum investment accepted was listed as $0. No sales commissions or finders' fees were reported, and no proceeds were allocated to named officers, directors or promoters.
Jaguar Health, Inc. (JAGX) filed a Form D Notice reporting a completed private equity offering under Rule 506(b) that raised $2,377,000. The filing identifies the issuer as a Delaware corporation with its principal place of business in San Francisco, CA. The offering sold all securities (Total Amount Sold: $2,377,000; Total Remaining to be Sold: $0) to a total of 15 investors. The minimum investment accepted was listed as $0. No sales commissions or finders' fees were reported, and no proceeds were allocated to named officers, directors or promoters.
Jaguar Health, Inc. filed an 8-K reporting a material event and attached corporate documents. The filing includes a Certificate of Designation of Preferences, Rights and Limitations of Series N Perpetual Preferred Stock, a Form of Securities Purchase Agreements, and an embedded Cover Page Interactive Data File within the inline XBRL document. The text defines a "Fundamental Transaction" to include transactions such as a sale, merger, consolidation, transfer of substantially all assets, sale or spin-off of subsidiaries, or any transaction where another person/group acquires more than 50% of outstanding common stock. The filing is signed by Lisa A. Conte, Chief Executive Officer & President and dated September 11, 2025.
Lincoln Alternative Strategies LLC filed a Form 3 reporting initial beneficial ownership in Jaguar Health, Inc. (JAGX). The filing states the reporting person holds 600,000 shares of Common Stock as a direct owner. The filing identifies the reporting persons relationship to the issuer as a Director and 10% owner. The statement is dated 08/28/2025 with a signature dated 08/29/2025.
Lincoln Alternative Strategies LLC disclosed ownership of 600,000 shares of Jaguar Health, Inc., representing 18.92% of the outstanding common stock based on 3,171,566 shares as of August 28, 2025. The filing shows Lincoln holds sole voting and sole dispositive power over all 600,000 shares. The Schedule 13G lists the issuer's and filer’s addresses and identifies the filer as a Delaware entity. The filer also certifies the shares were not acquired to change or influence control of the issuer.
Jaguar Health, Inc. held its 2025 Annual Meeting of Stockholders on August 19, 2025, where all seven proposals put to a vote were approved. The proposals were previously described in the company’s proxy statement.
Stockholders elected three directors to the board: James J. Bochnowski received 359,092 votes for and 21,757 withheld, Lisa A. Conte received 357,147 votes for and 23,702 withheld, and Jonathan B. Siegel received 361,236 votes for and 19,613 withheld; each director election had 425,060 broker non-votes. One proposal received 778,506 votes for, 13,484 against, and 13,919 abstentions, while several others each received over 321,000 votes for with 425,060 broker non-votes. The company also issued a press release summarizing these results, furnished as an exhibit.
Jaguar Health, Inc. held its 2025 Annual Meeting of Stockholders on August 19, 2025, where all seven proposals put to a vote were approved. The proposals were previously described in the company’s proxy statement.
Stockholders elected three directors to the board: James J. Bochnowski received 359,092 votes for and 21,757 withheld, Lisa A. Conte received 357,147 votes for and 23,702 withheld, and Jonathan B. Siegel received 361,236 votes for and 19,613 withheld; each director election had 425,060 broker non-votes. One proposal received 778,506 votes for, 13,484 against, and 13,919 abstentions, while several others each received over 321,000 votes for with 425,060 broker non-votes. The company also issued a press release summarizing these results, furnished as an exhibit.
Jaguar Health, Inc. Schedule 13G/A discloses that CVI Investments, Inc. and Heights Capital Management, Inc. collectively report beneficial ownership of 147,000 shares, equal to 9.9% of the class. The filing states the reported shares consist of shares issuable upon exercise of warrants and that the warrants are not exercisable to the extent exercise would cause ownership to exceed 9.99%. The company's prospectus reported 1,324,471 shares outstanding (excluding shares underlying the warrants) as of June 13, 2025.
The filing shows shared voting and dispositive power of 147,000 shares and no sole voting or dispositive power. Heights Capital serves as investment manager to CVI and may be deemed to exercise voting and dispositive power over the shares; both reporting persons disclaim beneficial ownership except for their pecuniary interest. The statement is signed by Sarah Travis on 08/12/2025 and references previously filed Limited Power of Attorney and Joint Filing Agreement exhibits.
Jaguar Health, Inc. announced a Sixth Amendment to its At-The-Market (ATM) Offering Agreement that extends Lucid Capital Markets, LLC's role as a Manager under the agreement. The amendment extends Lucid's term retrospectively from June 30, 2025 to December 31, 2025, unless the parties agree to a further extension.
The amendment clarifies that if the agreement is not otherwise amended or extended, Ladenburg Thalmann & Co. Inc. will remain as the sole Manager after December 31, 2025. The company also filed a prospectus supplement (referencing the May 23, 2024 supplement and May 1, 2024 prospectus) relating to the amendment, and attached the full amendment as Exhibit 10.1.
Jaguar Health, Inc. filed Supplement No. 6 to its ATM Prospectus Supplement to amend the At-The-Market Offering Agreement with Ladenburg Thalmann and Lucid Capital Markets. The amendment, dated August 14, 2025, extends Lucid's role as a Manager under the ATM Agreement retrospectively from June 30, 2025 through December 31, 2025, unless further extended, after which Ladenburg would be the sole Manager.
Since the ATM Prospectus Supplement dated May 23, 2024, the company has sold 1,370,282 shares under the ATM Program for gross proceeds of approximately $22.9 million, leaving approximately $1.66 million available for future sales. The last reported Nasdaq sale price on August 13, 2025 was $2.59 per share.